TRPV1 and neoplasm: Inspired by preferable antitumor efficacy and safety of IS-Micelles via TRPV1 blockade-synergized thermotherapy in TNBC models, we further evaluated their therapeutic potencies against highly aggressive human tumor models that also highly express TRPV1 channels, including HepG2 liver tumors, MDA-MB-231 breast tumors, HCT-116 colorectal tumors and PNAC1 pancreatic tumors18.